Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Sees Large Drop in Short Interest

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) saw a significant decrease in short interest in March. As of March 15th, there was short interest totalling 21,100 shares, a decrease of 60.9% from the February 28th total of 53,900 shares. Based on an average daily volume of 28,500 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.0% of the company’s shares are short sold.

Inhibitor Therapeutics Price Performance

Inhibitor Therapeutics stock opened at $0.06 on Thursday. The business has a fifty day moving average price of $0.06 and a 200-day moving average price of $0.07. Inhibitor Therapeutics has a 1-year low of $0.04 and a 1-year high of $0.14. The stock has a market capitalization of $9.51 million, a price-to-earnings ratio of -5.52 and a beta of -0.55.

Inhibitor Therapeutics Company Profile

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.